Articles from Beacon Therapeutics (USA), Inc.

LANDSCAPE open-label trial to evaluate safety of laru-zova administered bilaterally

LONDON and CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London, UK.

LONDON and CAMBRIDGE, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that members of its management team will participate in Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, in New York, NY.

LONDON and CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that members of its management team will participate in the 2025 Bank of America Healthcare Trailblazers Private Company Conference on Wednesday, September 17, 2025, in Boston, MA.

Data showed sustained improvements across several key measures of visual function, including low luminance visual acuity and microperimetry

LONDON and CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announces upcoming presentations on the preliminary 9+-month data from the Phase 2 DAWN trial and 36-month results of the randomized, controlled Phase 2 SKYLINE trial of the Company’s lead program, laru-zova (laruparetigene zovaparvovec), in patients with X-linked retinitis pigmentosa (XLRP) at the EURETINA 2025 Conference being held September 4-7, 2025 in Paris, France.

LONDON and CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (“Beacon Therapeutics” or ”the Company”), a leading clinical-stage biotechnology company with a mission to save and restore the vision of patients with blinding retinal diseases, today announces that it has successfully completed enrollment in its registrational Phase 2/3 VISTA trial evaluating laru-zova for the treatment of X-linked retinitis pigmentosa (XLRP).

Dr. Chung brings over three decades of experience spanning clinical ophthalmology, academic research and gene therapy development

Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry